Core Viewpoint - Bicara Therapeutics Inc. is advancing its clinical-stage bifunctional therapy, ficerafusp alfa, for treating recurrent/metastatic head and neck squamous cell carcinoma, with updated data to be presented at the 2025 ASCO Annual Meeting [1][2]. Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for patients with solid tumors [6]. - The lead program, ficerafusp alfa, is a first-in-class bifunctional antibody targeting both epidermal growth factor receptor (EGFR) and human transforming growth factor beta (TGF-β) [4][6]. Clinical Trial Information - Ficerafusp alfa is currently being evaluated in the pivotal Phase 2/3 clinical trial (FORTIFI-HN01) for first-line recurrent/metastatic head and neck squamous cell carcinoma [5]. - The updated results from an expansion cohort of an open-label, multicenter, Phase 1/1b trial will be presented at the ASCO meeting [3][8]. Presentation Details - The oral presentation is scheduled for June 1, 2025, from 12:12 to 12:18 p.m. CT at the McCormick Place Convention Center [8].
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting